Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bearish -50

BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

AI-generated analysis

πŸ“… Faruqi & Faruqi, LLP is reminding Boston Scientific (BSX) shareholders of the May 4, 2026 deadline to request a role as lead plaintiff in a federal securities class action.

🏒 The law firm alleges that BSX executives violated federal securities laws by making false or misleading statements regarding the company's U.S. EP segment.

⚠️ The complaint claims management knew the segment's growth was unsustainable and was approaching a tipping point earlier than anticipated.

πŸ“‰ Investors and analysts were left surprised when BSX reported a net income miss and issued underwhelming guidance for the first half of fiscal 2026.

πŸ—“οΈ On February 4, 2026, Boston Scientific published results showing disappointment in U.S. EP sales and guidance that fell below market expectations.

πŸ’¬ The company attributed its poor performance to slower-than-expected market growth and increased competition, contradicting prior claims of a "growing" business.

πŸ“‰ Following the negative news, BSX's stock price dropped $16.12 (a 17.6% decline) to close at $75.50 per share on February 4, 2026.

βš–οΈ Becoming a lead plaintiff involves serving as the investor with the largest financial interest in the relief sought and directing the litigation on behalf of the class.

πŸ‘₯ Shareholders may choose to serve as lead plaintiff, remain an absent member, or do nothing without affecting their ability to share in any recovery.

πŸ’° Faruqi & Faruqi states it has recovered hundreds of millions of dollars for investors since its founding in 1995 across multiple offices.

πŸ“ž Investors suffering losses are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss options.

πŸ” The firm also invites individuals with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to contact them.

πŸ’Ό This press release is classified as attorney advertising by Faruqi & Faruqi, LLP with prior results not guaranteeing similar outcomes.

Bullish Signals
  • No positive elements were found in this article as it is entirely a legal shareholder reminder regarding a securities class action, negative stock performance, and alleged misleading statements.
  • The law firm of Faruqi & Faruqi has recovered hundreds of millions of dollars for investors since its founding in 1995, demonstrating strong litigation track record.
Risk Factors
  • Boston Scientific (BSX) faced a significant stock price decline of $16.12, or 17.6%, closing at $75.50 per share on February 4, 2026, following the disclosure of disappointing results.
  • The company's net income missed expectations and issued underwhelming guidance for fiscal 2026, contradicting previous assertions of confidence in a 'growing' U.S. EP business.
  • Management's growth forecasts were proven unsustainable as the U.S. EP segment approached an earlier tipping point than anticipated by the market, leading to concerns over competitive pressures and slower market growth.
  • The securities class action alleges that executives violated federal securities laws by making false or misleading statements and failing to disclose the true state of the U.S. EP segment before February 4, 2026.
  • Investors who purchased securities between July 23, 2025, and February 3, 2026, suffered financial losses due to the company's failure to meet performance metrics and guidance targets.
Full Analysis
Faruqi & Faruqi, LLP has issued a shareholder reminder regarding a potential securities class action against Boston Scientific Corporation (NYSE: BSX), urging investors to contact the firm before May 4, 2026. The firm is investigating allegations that the Company and its executives violated federal securities laws by making false or misleading statements and failing to disclose critical information about the true state of Boston Scientific's U.S. EP (Electrophysiology) segment. Specifically, the complaint claims management knew the segment's growth rate was unsustainable and approaching a tipping point earlier than anticipated by the market, yet provided confidence-inspiring statements that misled investors and analysts. The legal action stems from financial disclosures made on February 4, 2026, when Boston Scientific released its fourth quarter and full year 2025 results, revealing a significant disappointment in U.S. EP sales and issuing guidance for fiscal 2026 that fell well below expectations. Although the company attributed these poor results to slower-than-expected market growth and increased competition, investors argue this contradicted previous management assertions of a "growing" EP business and a strong understanding of competitive threats. Upon the announcement of these disappointing results, Boston Scientific's stock price dropped $16.12, representing a 17.6% decline to close at $75.50 per share on February 4, 2026, which the firm states caused financial injury to shareholders. The notice highlights that May 4, 2026, is the deadline for investors to seek the role of lead plaintiff in the federal class action filed against the company. According to the filing, the court-appointed lead plaintiff must be an investor with the largest financial interest who directs and oversees litigation on behalf of the class; however, any member of the putative class may move the court to serve as lead plaintiff through counsel of their choice or remain an absent class member without affecting their ability to share in any recovery. The law firm has also encouraged anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to contact them directly for potential whistleblower claims. Investors affected are urged to have purchased or acquired securities in Boston Scientific between July 23, 2025, and February 3, 2026, and may discuss their options by contacting Partner James (Josh) Wilson at Faruqi & Faruqi, LLP via phone at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm, which has recovered hundreds of millions for investors since its founding in 1995 and maintains offices in New York, Pennsylvania, California, and Georgia, directs further inquiries to their website at www.faruqilaw.com/BSX or via their LinkedIn, X, and Facebook channels for updates.